Business Standard

Friday, December 27, 2024 | 09:45 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cadila hits 52-week low on 14 observations from USFDA for Moraiya plant

The US Food and Drug Administration has issued 14 observations after inspecting the drug firm's manufacturing facility at Moraiya in Ahmedabad.

Cadila Healthcare, Moraiya
Premium

File photo of Cadila Healthcare's Moraiya facility

SI Reporter Mumbai
Cadila Healthcare shares hit a 52-week low of Rs 292, down 4 per cent in early morning trade on Monday, extending its Friday’s 3.5 per cent fall on the BSE, after getting 14 observations from US health regulator for its Moraiya plant.

The US Food and Drug Administration (USFDA) have issued 14 observations after inspecting its manufacturing facility at Moraiya in Ahmedabad, Cadila Healthcare said in a regulatory filing. 

The USFDA inspected the plant from April 22, 2019 to May 3, 2019. The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in